drugset / Trial / NCT05381506
Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This study aims to investigate the treatment of refractory or relapsed DLBCL with orelabrutinib and gemox. The primary endpoint is response rate (complete response rate and overall response rate), and the second endpoints are survival time (OS and PFS) and toxicities.
Timeline
- Start
- 2022-07
- Primary completion
- 2023-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | — | — |
| Subject | Orelabrutinib | Small molecule | 200 mg | Oral |
| Subject | Oxaliplatin | Small molecule | — | — |